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Summary: The hazard ratio (HR) has been the most popular measure to quantify the magnitude of treatment effect
on time-to-event outcomes in clinical research. However, the HR estimated by Cox’s method has several drawbacks.
One major issue is that there is no clear interpretation when the proportional hazards (PH) assumption does not
hold, because it is affected by study-specific censoring time distribution in non-PH cases. Another major issue is that
the lack of a group-specific absolute hazard value in each group obscures the clinical significance of the magnitude of
the treatment effect. Given these, we propose average hazard with survival weight (AH-SW) as a summary metric of
event time distribution and will use difference in AH-SW (DAH-SW) or ratio of AH-SW (RAH-SW) to quantify the
treatment effect magnitude. The AH-SW we propose is a new digestible metric interpreted as a person-years event
rate when random censoring would not exist. It is defined as the ratio of τ -year event rate and restricted mean survival
time, which can be estimated non-parametrically. Numerical studies demonstrate that DAH-SW and RAH-SW offer
almost identical power to Cox’s method under PH scenarios and can be more powerful for delayed-difference patterns
that are often seen in immunotherapy trials. The proposed metrics (i.e., AH-SW, DAH-SW and RAH-SW) and the
inferential methods for them offer a digestible interpretation that the conventional Cox’s method could not provide
about the survival benefit of a new therapy. These metrics will increase the likelihood that results from clinical studies
are correctly interpreted.
Key words: Hazard ratio; immunotherapy studies; non-proportional hazards; person-years event rate; t-year
survival rate; restricted mean survival time.
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1. Introduction
The magnitude of treatment effect on time-to-event outcomes, such as overall survival (OS)
and progression-free survival (PFS), is almost routinely explained using the hazard ratio
(HR). A recent study showed that more than 95% studies used the HR in contemporary phase
III randomized trials in oncology (Uno et al., 2020). The standard method to estimate HR is
based on the partial likelihood score equation proposed by Cox (1972, 1975). However, the
HR based on Cox’s method has several drawbacks (Kalbfleisch and Prentice, 1981; Struthers
and Kalbfleisch, 1986; Lin and Wei, 1989; Hernán, 2010; Uno et al., 2014). One notable issue
is that when the proportional hazards (PH) assumption does not hold, the result depends
on the underlying study-specific censoring time distribution (Kalbfleisch and Prentice, 1981;
Schemper, 1992; Xu and O’Quigley, 2000; Horiguchi et al., 2019). In these non-PH cases,
interpretation of the HR is not clear.
Another major issue is the lack of a reference number from the control group. This reference
number is a summary metric of event time distribution in the control group that can serve as
a reference for the corresponding between-group contrast measure to quantify the treatment
effect magnitude. For example, when the difference or ratio of response rates from two groups
is used for reporting the treatment effect on tumor response in a cancer trial, the reference
number will be the response rate in the control group. The lack of a reference number
for Cox’s HR is not a statistical problem but rather a practical one that arises during
clinician/patient treatment decision making. This can be seen in an example clinical study
that uses the risk ratio (RR) to report the treatment effect magnitude. The risk reduction
from 50% (control) to 40% (treatment) and that from 1% (control) to 0.8% (treatment) give
the exact same RR=0.8 (i.e., 20% of risk reduction). However, the clinical implication would
be quite different, depending on the absolute risk in the control group. As such, a reference
number from the control group plays an important role in determining whether the observed
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between-group summary measure indicates a clinically meaningful treatment benefit/risk.
Unfortunately, we do not have such a reference number for Cox’s HR. Cox’s model has a
baseline hazard function; however, this is not a number but a function of time.
These points regarding the issues of HR have been reported in the General Statistical
Guidance provided by the Annals of Internal Medicine. It states, “... Hazard ratios are
notoriously difficult to interpret clinically, may be sensitive to the length of follow-up, and
rely on model assumptions, such as proportional hazards. In addition, presenting estimates of
effect in both absolute and relative terms increases the likelihood that results will be correctly
interpreted...” (Annals of Internal Medicine). However, with a reference number it would be
possible to present the treatment effect in both absolute and relative terms.
To address the first issue of Cox’s HR, several alternative approaches have been already pro-
posed (Kalbfleisch and Prentice, 1981; Schemper, 1992; Xu and O’Quigley, 2000). Kalbfleisch
and Prentice (1981) proposed the “average” hazard ratio (AHR). Borrowing the expression
by Schemper et al. (2009), a general form of the AHR is given by
AHR =
∫
[h1(t)/{h0(t) + h1(t)}]w(t){f0(t) + f1(t)}dt∫
[h0(t)/{h0(t) + h1(t)}]w(t){f0(t) + f1(t)}dt
, (1)
where hk(·) and fk(·) are the hazard function and the density function of the event time Tk
for group k, respectively, for k = 0, 1, and w(·) is a weight function. When w(t) = 1, AHR
is a HR of the standard Cox (Schemper et al., 2009). Let Sk(t) denote the survival function




P (T1 < T0)
1− P (T1 < T0)
, (2)
which is called the odds-of-concordance (Schemper et al., 2009).
Another approach to address the first issue of Cox’s HR is using weighted Cox regression
(Schemper, 1992; Xu and O’Quigley, 2000). The problem with Cox’s method is that the
limiting quantity of the partial likelihood score equation involves censoring time distribution
when the PH assumption does not hold. Xu and O’Quigley (2000) proposed using inverse
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probability censoring weights, so that the censoring time distribution can be removed from
the limiting quantity of the estimating equation without imposing the PH assumption. The
resulting HR estimate from this estimating equation can be interpretable as an AHR.
Unlike Cox’s method, the estimates for the AHR derived from these alternative methods
will not depend on a study-specific random censoring time distribution regardless of whether
the PH assumption holds or not. Therefore, the interpretation of the resulting AHR esti-
mates would still be possible even under non-PH scenarios. However, although these AHR
approaches address the first issue of Cox’s HR, it is not clear if they address the second
issue of Cox’s HR. One may try to calculate the average hazard in the control group, as a
reference number for AHR, by standardizing the term in the denominator of the equation
(1) or (2). However, it may be difficult to interpret this number as an absolute hazard of the
control group because it involves the event time distribution of the treatment group.
Given the limitations on Cox’s HR and these AHR approaches, non-hazard-based alterna-
tive metrics to summarize treatment effect magnitude are gaining attention (Royston and
Parmar, 2011; Uno et al., 2014, 2015; A’Hern, 2016; Chappell and Zhu, 2016; Péron et al.,
2016; Saad et al., 2018). For example, the difference or ratio of restricted mean survival
time (RMST) is a good alternative measure that does not have the first or second issue we
discussed above. However, availability of such non-hazard-based alternative measures will
not resolve all the problems in practice. Since the summary measure should be selected
to address clinical research questions that are highly variable, there will still exist many
situations where investigators prefer to use a summary metric based on “hazard.”
These provide motivation for developing novel summary measures for quantifying the
treatment effect based on average hazards (AH) from two groups. We propose a ratio of
average hazard (RAH) and difference in average hazard (DAH) that can be consistently
estimated and have interpretations regardless of whether the PH assumption holds or not.
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In the proposed method, a reference number from the control group is also available. We
provide the details of the proposed measures and inference procedures for them (Section 2).
We conduct numerical studies to assess the performance of the proposed method in finite
sample size situations (Section 3). We also compare performance of the proposed method
with Cox’s method in the real-world setting using empirical data from recently conducted
phase III cancer trials (Section 4). We illustrate how the proposed method can help clinical
investigators with the interpretation of treatment effect by using the data from a recently
conducted immunotherapy trial (Section 5), followed by some remarks (Section 6).
2. Method
2.1 Average Hazard with Survival Weight
Let Tk be a continuous non-negative random variable to denote the event time for group
k (k = 0, 1). Let Ck denote the censoring time for group k. Assume that Tk is indepen-
dent of Ck. Let {(Tki, Cki); i = 1, . . . , nk} denote independent copies from (Tk, Ck). Let
Xki = min(Tki, Cki) and ∆ki = I(Tki 6 Cki), where I(A) is the indicator function for
event A. The observable data is then denoted by {(Xki,∆ki); i = 1, . . . , nk} . We assume
pk = limn→∞ nk/n > 0 for k = 0, 1, where n = n1 + n0.
Let hk(·) be the hazard function for Tk. For a given weight function, wk(·), the average








When wk(t) = 1 for t ∈ [0, τ ], ηk(τ) = Hk(τ)/τ, whereHk(·) is the cumulative hazard function
of Tk. It can be also expressed as ηk(τ) = − log{Sk(τ)}/τ, where Sk(·) is the survival function
for Tk. Let us call this the average hazard with equal weight (AH-EW). Difference or ratio
of the AH-EW can be a between-group summary measure to quantify the treatment effect
measure. However, we pursue neither in this paper, because it is essentially the same as the
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difference or ratio of the cumulative hazard function at τ. The inference procedures of these
quantities were already investigated extensively (Fleming and Harrington, 1991).
Here, we propose the average hazard with survival weight (AH-SW) using Sk(t) for the
weight function. When wk(t) = Sk(t), the numerator of ηk(τ) is denoted by the event rate at















Sk(t)dt, and compare it with the







F (t). We notice that
the AH-SW has a somehow similar form to the hazard function.
The rationale for proposing wk(t) = Sk(t) as the weight are as follows. First, Sk(t) is a
decreasing function of time and independent of study-specific censoring time distribution.
Because the number of subjects at risk is decreasing as t increases, the precision in estimating
hk(t) will also be decreasing along with t. From this point of view, one may consider Pr(Xk >
t) as a weight function in order to take the size of risk set into account for calculating the AH.
However, the interpretation of the AH with w(t) = Pr(Xk > t) = Pr(min(Tk, Ck) > t) will
be rather challenging, because this weight involves the study-specific censoring distribution,
Ck.
Second, for a pair of event time random variables, T0 and T1, the AH-SW does not
contradict with their stochastic order. For a given τ, suppose T0 is less than T1 in the
usual stochastic order, that is, Pr(T0 > t) 6 Pr(T1 > t) for all t ∈ (0, τ). This implies
that F0(τ) > F1(τ) and R
−1
0 (τ) > R
−1
1 (τ). Therefore, η0(τ) > η1(τ). This would an ideal
characteristic of the AH-SW because it will not produce a counterintuitive result when the
survival function from one group is uniformly higher than that from another group. The
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AH-EW also has this characteristic, but AH with some other weight functions may not hold
this.
Third, with wk(t) = Sk(t), the AH becomes a metric that would significantly help inter-
pretation of the analytical results of time-to-event outcomes. Specifically, the AH-SW can be
interpreted as the person-years event rate when general random censoring would not exist.




i=1 ∆kiI(Xki 6 τ)∑nk
i=1(Xki ∧ τ)
,
where τ it typically the maximum event time or censoring time in the observed data. In




i=1Xki. It is well known that, when
the distribution of Tk follows an exponential distribution with a parameter λk, λ̂k(τ) is the
maximum likelihood estimator for λk and it is consistent. However, when this distribution
assumption is not correct, λ̂k(τ) will converge to a quantity that involves a study-specific
censoring time distribution. In fact, when the distribution assumption is not correct, λ̂k(τ)
coverges in probability to
λ∗k(τ) =
E {I(Tk < Ck ∧ τ)}
E {(Tk ∧ Ck) ∧ τ}
=




where SCk(·) is the survival function for Ck. Now, suppose there is no random censoring
in the sense that Pr(Ck > τ) = 1. In this case, Fk(Ck ∧ τ) = Fk(τ) and SCk(u) = 1 for
u ∈ (0, τ) in the equation (3). Therefore, λ∗k(τ) = Fk(τ)/Rk(τ), which is identical to the
AH-SW. This derivation demonstrates that the AH-SW is a summary metric of Tk that has
a clear interpretation — the average person-years event rate of Tk on t ∈ (0, τ) when all Tk
before τ would have been observed without being censored by study-specific censoring time
Ck.





du, and F̂k(·) is the Kaplan-Meier estimator for Fk(·). For the inference of
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the AH-SW for group k, we consider Qk = n
1/2
k {log η̂k(τ)− log ηk(τ)} . In Appendix A, we













where Gk(t) = Pr(Xk > t). This variance can be estimated by replacing the unknown

















i=1 I(Xki > t), and Ĥk(·) is the Nelson-Aalen estimator for the
cumulative hazard function for group k.









where z1−α/2 is the (1− α/2)× 100-percentile of the standard normal distribution.
2.2 Ratio of Average Hazard with Survival Weight










Interestingly, the RAH-SW is expressed as a product of the ratio of τ -year event rate
(treatment (k = 1) versus control (k = 0)) and the ratio of RMST (control (k = 0)
versus treatment (k = 1)) at τ. The equation (4) gives another insight about the RAH-
SW. Suppose limt→∞ Fk(t) = 1, for k = 0, 1. This implies that limt→∞Rk(t) = E(Tk), for
k = 0, 1. Therefore, for a large τ such that Fk(τ) is close to 1 for k = 0, 1, θ(τ) can be viewed
as an approximation of the ratio of mean survival times from two groups (control versus
treatment), similar to the ratio of RMST.
The estimator for (4) is θ̂(τ) = η̂1(τ)/η̂0(τ). For hypothesis testing and interval estimation,
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we consider the asymptotic distribution of
n1/2
{
log θ̂(τ)− log θ(τ)
}
= n1/2 {log η̂1(τ)− log η1(τ)} − n1/2 {log η̂0(τ)− log η0(τ)} .
From the results regardingQk described in Section 2.1, it is obvious that n
1/2
{
log θ̂(τ)− log θ(τ)
}
converges weakly to a normal distribution with mean zero and variance p−11 V (Q1)+p
−1
0 V (Q0).
The variance can be estimated by n
{




. Therefore, an (1−α) asymp-










For testing the null hypothesis log θ(τ) = 0,
log θ̂(τ)/
√
n−11 V̂ (Q1) + n
−1
0 V̂ (Q0) (6)
is used as the test statistic, which asymptotically follows the standard normal distribution
under the null hypothesis.
2.3 Difference in Average Hazard with Survival Weight
We consider the difference in average hazard with survival weight (DAH-SW). Using the
same notations as we used for the RAH-SW, the DAH-SW is given by


















= n1/2 {η̂1(τ)− η1(τ)} − n1/2 {η̂0(τ)− η0(τ)} .
In Appendix B, we show that Uk = n
1/2
k {η̂k(τ)− ηk(τ)} converges weakly to a normal


















converges weakly to a normal distribution
with mean zero and variance p−11 V (U1) + p
−1
0 V (U0), which can be estimated by replacing
the unknown quantities by their empirical counterparts. Thus, an (1−α) asymptotic CI for
ξ(τ) is given by
ξ̂(τ)± z1−α/2
√
n−11 V̂ (U1) + n
−1
0 V̂ (U0), (7)
where V̂ (Uk) is the variance estimator for V (Uk), (k = 0, 1).
For testing no treatment effect (i.e., ξ(τ) = 0), we will use
ξ̂(τ)/
√
n−11 V̂ (U1) + n
−1
0 V̂ (U0) (8)
as the test statistic, which asymptotically follows the standard normal distribution under
the null.
As described above, RAH-SW and DAH-SW can be consistently estimated non-parametrically
regardless of whether the PH assumption holds or not. Also, a reference number from the
control group, η0(τ), will help clinical investigators assess if the resulting RAH-SW (or DAH-
SW) indicates a clinically meaningful magnitude or not. These will provide new interpretation
of the hazard-based treatment effect that the existing methods could not offer. In Section 5,




We evaluated finite sample properties of the proposed asymptotic CIs for RAH-SW and
DAH-SW and asymptotic tests for no treatment effect (i.e., RAH-SW=1 and DAH-SW=0)
via numerical studies. Four patterns of difference between two event time distributions were
10
considered — (A) No difference, (B) PH difference, (C) Early difference, and (D) Delayed
difference (Figure 1).
[Figure 1 about here.]
The pattern (A) was included for evaluating the empirical type I error rate of the proposed
tests. We used Weibull distributions to generate the event times for both groups. Specifically,
for the treatment group, we used the Weibull distributions with shape and scale parameters
of (1, 10), (1, 12.5), (1.5, 10), and (0.8, 15) for the patterns (A) to (D), respectively. For the
control group, we used the Weibull distribution with shape and scale parameters of (1, 10)
for all the patterns. Regarding censoring, we considered three patterns — (I) No censoring,
(II) Light censoring, and (III) Heavy censoring (Figure 2), all of which had an administrative
censoring at time 10. The fractions of censored observations at time 10− were 0, 0.3, and 0.7
for (I), (II), and (III), respectively. Regarding the sample size, we considered two scenarios
— n=100 and n=300 per arm. As such, we simulated a total of 24 configurations.
[Figure 2 about here.]
For each of the 24 simulation configurations, first, we generated n pairs of event time and
censoring time for each group {(Tki, Cki); k = 0, 1, i = 1, . . . , nk} independently. Note that
censoring time was independent of the event time and the same censoring distribution was
used for both groups. We then derived the observable data {(Xki,∆ki); k = 0, 1, i = 1, . . . , nk},
where Xki = min(Tki, Cki) and ∆ki is equal to 1 if Tki 6 Cki and 0 otherwise. With this data,
we estimated RAH-SW and DAH-SW, constructed the 0.95CI for them using (5) and (7),
respectively. Between-group comparisons were performed using the test statistics presented
in (6) and (8) at two-sided 0.05 α level. We used τ=10 for the truncation time point for all
scenarios. Repeating this process 5,000 times, we assessed the empirical bias of the proposed
estimators for RAH-SW and DAH-SW, the empirical coverage probability of the proposed
CIs, the average length of the CIs, and the empirical size and power of the tests.
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As a reference, we included the HR based on Cox’s method and assessed bias and coverage
probability. It is somewhat difficult to determine what the true value for Cox’s HR is under
non-PH scenarios (Early difference (Figure 1C) and Delayed difference (Figure 1D)), because
the population parameter to be estimated by Cox’s method depends on the censoring time
distribution when the PH assumption does not hold. In our simulations, we calculated the
value for each non-PH scenario with the no censoring pattern (Figure 2-I), and called it
”true” for Cox’s HR.
For assessment of the empirical size and power of the tests, we also included tests based
on the ratio of τ -year event rate and ratio of RMST as well as Cox’s method. Because the
RAH-SW is denoted by a product of the ratio of τ -year event rate and ratio of RMST
(4), inclusion of these components would be interesting. Regarding the ratio of τ -year event
and ratio of RMST, details of the test statistics used in our numerical studies are given in
Appendix C. For the group comparison by Cox’s method, the Wald test was used.
3.2 Results
We confirmed that the empirical bias of the proposed estimators for RAH-SW and DAH-
SW was negligibly small and the coverage probability is sufficiently close to the nominal
level for all scenarios with n=100 per arm (Table 1) and n=300 per arm (Table 2). On the
other hand, as expected, we observed that Cox’s HR gave us a biased estimate and the CI
did not achieve the nominal coverage level under non-PH scenarios (i.e., Early and Delayed
differences; Figures 1C and 1D) with the presence of light and heavy censoring (Figures
2-II and 2-III). The most pronounced case in our study was the combination of the early
difference pattern (Figure 1C) and heavy censoring pattern (Figure 2-III) with n=300 per
arm (Table 2). In this case, the bias of Cox’s HR was -0.091, roughly 10% of the true HR
(0.901). The coverage probability of 0.95CI based on Cox’s method was 0.854, which was
much lower than the nominal level 0.95. The average length of the CI of the RAH-SW was
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almost identical to that of Cox’s method for the no and light censoring patterns (Figures 2-I
and 2-II), but it was slightly wider with heavy censoring scenarios (Figure 2-III) except for
the delayed difference scenario (Figure 1D). For the delayed difference scenario (Figure 1D),
no remarkable difference was seen in the average length of the CIs between RAH-SW and
Cox’s HR regardless of the censoring pattern.
[Table 1 about here.]
[Table 2 about here.]
The results of the five tests we considered are presented in Table 3 (for n=100) and Table
4 (for n=300.) First, the empirical size was assessed with the no difference pattern (Figure
1A). Since the number of iterations was 5,000, we considered that the empirical size should
be within 0.044 to 0.056 with 95% chance if the true type I error rate is 5.0%. The empirical
sizes of these tests were within this range except for the test based on the ratio of τ -year
event rate with the combination of n=100 and heavy censoring (Figure 2-III).
Under the PH difference pattern (Figure 1B), power of the tests based on RAH-SW and
DAH-SW were comparable to that of Cox’s HR with no, light and heavy censoring patterns
for both n=100 (Table 3) and n=300 (Table 4).
Under the early difference pattern (Figure 1C), the power of RAH-SW, DAH-SW and
Cox’s HR were similar with the no censoring case, but Cox’s HR offered higher power with
light and heavy censoring cases. The test based on RMST was superior for all censoring
patterns for this scenario. The test based on τ -year event rate was the worst.
Under the delayed difference pattern (Figure 1D), again, for the no censoring case, no
remarkable difference was seen among RAH-SW, DAH-SW and Cox’s HR. However, with
the presence of censoring, RAH-SW and DAH-SW gave higher power than Cox’s HR. For
this scenario, the test based on RMST was the worst for all censoring patterns. The test
based on τ -year event rate gave the highest power.
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RAH-SW and DAH-SW are comprised of ratio of τ -year event rate and ratio of RMST. As
expected, the power of RAH-SW and DAH-SW were between tests based on ratio of τ -year
event rate and ratio of RMST under the non-PH scenarios (Figures 1C and 1D). Interestingly,
under the PH scenario (Figure 1B), RAH-SW and DAH-SW were more comparable to Cox’s
method than tests based on ratio of τ -year event rate and ratio of RMST.
In sum, in terms of power, RAH-SW and DAH-SW can be recommended when the expected
pattern is PH difference or delayed difference. Throughout the scenarios, the performance of
RAH-SW and DAH-SW were almost identical.
[Table 3 about here.]
[Table 4 about here.]
4. Empirical power comparisons with data from recent cancer clinical trials
The performance of a new method is usually assessed by Monte Carlo simulation studies as
we presented in the previous section. However, these numerical studies rely on artificial data
and simulation configurations are limited. In this section, we assessed the proposed method
using empirical data to provide more convincing real-world evidence. Specifically, we used
the same set of data used by Horiguchi et al. (2020). It consists of reconstructed patient-level
data for OS and PFS from 69 and 54 phase III cancer trials, respectively. These studies were
selected from the papers published in one of seven journals (Journal of the American Medical
Association, JAMA Oncology, Journal of Clinical Oncology, Journal of the National Cancer
Institute, Lancet, Lancet Oncology, and New England Journal of Medicine) between July
1st, 2016 and June 30th, 2017. Details of the eligibility criteria for the papers and studies
are found in Horiguchi et al. (2020). The algorithm proposed by (Guyot et al., 2012) was
used to reconstruct patient-level data from the figures in these papers.
We applied the tests based on RAH-SW and DAH-SW, and the Wald test via Cox’s model
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to each study data and compared their empirical power for OS and PFS, separately. The
truncation time point for RAH-SW and DAH-SW was set to the study time point where the
number at risk was at least 30 in both groups. Here, the empirical power was defined as the
proportion of studies where the test gave a significant p-value (i.e., 6 0.05 (two-sided)).
Figure 3 shows scatter plots of p-values from the tests based on RAH-SW and Cox’s
method for OS (3A) and PFS (3B). Most of the studies were distributed around the 45 degree
diagonal line for both OS and PFS. We did not see a significant difference between the two
tests in terms of empirical power. For OS, the empirical power of RAH-SW was 43.5%, which
was numerically higher than that of Cox’s method (37.7%). The difference (RAH-SW minus
Cox’s) was 5.8% and a corresponding 0.95CI (Liu et al., 2002) was -2.1% to 13.7%. We also
did not observe a notable difference between the two tests for PFS. The empirical power of
RAH-SW was identical to that of Cox’s method (59.3%). The 0.95CI for the difference in the
empirical power was -5.1% to 5.1%. The same analyses were performed for the test based on
DAH-SW. Similar to the results of the numerical studies in the previous section, RAH-SW
and DAH-SW provided almost identical performance. The empirical power of DAH-SW was
almost identical to that of RAH-SW (results not shown). These results suggest that there is
no clear power advantage of exclusively using Cox’s method for all studies.
[Figure 3 about here.]
5. Example
We illustrate the proposed method using the data from a randomized phase III trial to
compare nivolumab plus ipilimumab (treatment) with sunitinib (control) in patients with
previously untreated clear-cell advanced renal-cell carcinoma (CheckMate 214 study). A total
of 847 patients (425 for the treatment group and 422 for the control group) served for the
analysis of PFS. We reconstructed patient-level data from the results reported by Motzer
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et al. (2018), using the method proposed by Guyot et al. (2012). Figure 4 presents the
Kaplan-Meier curves for PFS with the reconstructed patient-level data.
[Figure 4 about here.]
The two curves were similar to each other up to around 6 months and then diverged. This
pattern of difference is the so-called “delayed difference” that is often seen in immunotherapy
trials. Cancer immunotherapy does not attack cancer cells directly but instead directs the
immune system to do so. It is believed that it takes time for immunotherapy to activate the
immune system and thus, this would be a reason why the two Kaplan-Meier curves show
such a delayed difference pattern. The HR (treatment over control) based on Cox’s method
was 0.82 (0.95CI: 0.68 to 0.99, p-value=0.037). The p-value of the cumulative residual test
(Lin et al., 1993) for this study was not significant (0.084). However, it is important to note
that a non-significant p-value from the PH assumption test does not imply that the PH
assumption is indeed true.
We estimated the AH-SW, τ -year event rate, and RMST for each group. For each metric,
we estimated both absolute difference (treatment minus control) and ratio (treatment over
control) and corresponding 0.95CIs and p-values. The results were summarized in Table 5.
Note that, in this example, we chose 21 (months) for τ because the number at risk at 21
months was greater than 30 for both groups (Figure 4). The estimated AH-SWs for the
treatment and control groups were 0.049 (0.95CI: 0.042 to 0.057) and 0.066 (0.95CI: 0.057
to 0.076), respectively. The RAH-SW was 0.747 and the corresponding 0.95CI was (0.608 to
0.917). The p-value for testing RAH-SW=1 was 0.005. The estimated DAH-SW was -0.017
(0.95CI: -0.029 to -0.005). The resulting p-value for testing DAH-SW=0 was 0.006.
Similar to the τ -year event rate and RMST, using the AH-SW as a summary of event time
distribution allows us to express the treatment effect in both absolute and relative terms
(i.e., DAH-SW and RAH-SW). Moreover, since the AH-SW is the person-time event rate
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when random censoring would not exist, DAH and RAH would be much more digestible
than Cox’s HR for clinical researchers. From the results, the event rates in the treatment
group and control group, on average, are 4.9 events and 6.6 events per 100 at risk subjects
per month, respectively. The RAH-SW 0.747 means that the combination of immunotherapy
(nivolumab plus ipilimumab) reduces the event rate in the control (sunitinib) group by 25.3%
on average. Note that Cox’s HR approach cannot provide such a digestible interpretation
due to the lack of a group-specific absolute hazard value in each group. We consider this is a
notable advantage of using RAH-SW or DAH-SW over the conventional Cox’s HR approach.
[Table 5 about here.]
6. Remarks
In this paper, we proposed AH-SW, a new summary metric of event time distribution, and
RAH-SW and DAH-SW for quantifying the treatment effects and inference procedure for
these metrics. The proposed method offers clinical investigators with a tool to summarize
the hazard-based treatment effect magnitude in both absolute and relative terms. We believe
this can be a solution that addresses the comments in the General Statistical Guidance by
the Annals of Internal Medicine we introduced in Section 1.
RAH-SW and DAH-SW have several beneficial properties. First, they can be estimated
consistently without imposing a strong model assumption (such as the PH assumption)
between two event time distributions. Second, the AH-SW values from two groups used
for RAH-SW and DAH-SW are available. These help us assess if the resulting RAH-SW (or
DAH-SW) indicates a clinically meaningful treatment effect magnitude or not. As we showed
in Section 5, using the proposed method enables us to provide a new digestible interpretation
of the hazard-based treatment effect that was not possible with the conventional Cox’s
method. Third, neither RAH-SW or DAH-SW contradicts the stochastic ordering of two
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event time distributions on [0, τ ]. That is, when a survival curve from Group A is always
located higher than that from Group B on the time range [0, τ ], the AH-SW of Group A
is always lower than that of Group B, which indicates that Group A is better than Group
B. Forth, they will always be reported along with the truncation time point τ, which will
enhance understanding regarding the limitations about generalization of the study findings.
Lastly, RAH-SW and DAH-SW offer similar power to Cox’s method when the PH assumption
holds. Also, our numerical studies demonstrated that they can be more powerful than Cox’s
method for the delayed difference patterns that are often seen in immunotherapy trials.
Regarding adjustment for prognostic factors, a stratified analysis with the proposed method
would be straightforward. The proposed method can be extended to apply to observational
data, such as when Conner et al. (2019) used it for estimating adjusted difference in RMST.
Specifically, one can use the inverse probability weighting approach to get the adjusted
Kaplan-Meier curve for the event time distribution in each group. Then, τ -year event rate,
RMST, and AH-SW can be easily derived for each group.
Similar to RMST-based analyses, the choice of the truncation time τ is an important
point to be addressed. For confirmatory studies, τ should be pre-specified in the study
protocol. Given that the study findings are limited to the range of the study time, it would
be possible to elicit a pre-specified τ at the design stage by considering the clinical questions
investigators would like to have answered by that study. For example, if investigators believe
that evaluating long-term treatment effect (e.g., 2 years) is necessary to determine whether
the investigative drug is useful, τ will be 2 years. The patient accrual schedule and the
additional follow-up time will be determined accordingly, so that the size of risk set at τ
can be sufficiently large to rely on the large sample theories in both groups. When designing
a study using conventional Cox’s HR approach, investigators are projecting how long the
study follow-up needs to be in order to observe a required number of events to achieve a
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desired power. Therefore, we believe that such a number must exist in investigators’ mind,
even if vaguely.
Because the study findings are limited to the duration of the study time, clarifying the
truncation time τ is important to enhance understanding of the treatment effect and its
limitation regarding generalization. Related to this, it is important to note that Cox’s HR also
has an implicit truncation time point since information beyond that time point (i.e., the time
when the last event was observed or the time when the size of risk set in either group became
0, whichever occurred first) does not contribute inference of the HR. Conventionally, such
an implicit truncation time point has not been reported along with Cox’s HR. However, we
believe that it would be a good practice to explicitly report the truncation time τ regardless
of the metric used for summarizing the treatment effect.
Since the variance formulae for log θ̂(τ) and ξ̂(τ) are given in this paper, the sample size
calculation for designing a study using RAH-SW or DAH-SW would be straightforward. To
calculate, one will specify the distributions of event time and censoring time for each group,
the truncation time τ, and the ratio to allocate subjects to group 1, and determine log θ(τ)
(or ξ(τ)) and the variances V (Q0) and V (Q1) (or V (U0) and V (U1)). The required total
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Appendix A. Large sample properties of Qk
We use the same notation and the assumption in Section 2. First, we note well-known results

















and this converges weakly to a zero-mean normal distribution, where Gk(t) = Pr(Xk > t),
Mki(t) = Nki(t) −
∫ t
0
Yki(s)dHk(s), Nki(t) = I(Xki 6 t,∆ki = 1), and Yki(t) = I(Xki > t).


















which converges weakly to a zero-mean normal distribution.
Next, applying the Taylor series expansion, coupled with the results of (A.1) and (A.2),
Qk = n
1/2

































By the martingale central limit theorem, it is shown that Qk converges weakly to a normal













Appendix B. Large sample properties of Uk
We rewrite Uk = n
1/2
k {F̂k(τ)/R̂k(τ)− Fk(τ)/Rk(τ)} by
Uk = n
1/2
k {F̂k(τ)/R̂k(τ)− Fk(τ)/R̂k(τ)}+ n
1/2
k {Fk(τ)/R̂k(τ)− Fk(τ)/Rk(τ)}. (A.3)
By the application of Taylor series expansion, coupled with the results of (A.1) and (A.2),
it is shown that the first term of (A.3) is n
1/2
k {F̂k(τ)/Rk(τ) − Fk(τ)/Rk(τ)} + op(1). Also,
by the application of Taylor series expansion to the second term of (A.3), coupled with the
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Therefore, by the martingale central limit theorem, it is shown that Uk converges weakly to













Appendix C. Test statistics used in the simulation study
For group comparisons based on ratio of τ -year event rate and ratio of RMST, we used
the following results. From (A.1) and (A.2), WFk = n
1/2
k {log F̂k(τ) − logFk(τ)} and WRk =
n
1/2
k {log R̂k(τ) − logRk(τ)} converge to zero-mean normal distribution with the variance


















, respectively. Thus, for















n−11 V̂ (WR1 ) + n−10 V̂ (WR0 ) as the
test statistic, respectively.
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Figure 1. Survival functions of event time distributions of the treatment group (solid
line) and control group (dashed line) used in the numerical studies. A, no difference; B,
proportional hazards difference; C, early difference; D, delayed difference.
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Figure 2. Survival functions of censoring time distributions used in the numerical studies.
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Figure 3. Scatter plots of p-values from the tests based on ratio of average hazard with
the survival weight (RAH-SW) and Cox’s method for A) overall survival (69 studies) and
B) progression-free survival (54 studies).
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Figure 4. The Kaplan-Meier curves of progression-free survival time for nivolumab plus
ipilimumab group (solid line) and sunitinib group (dashed line) with the data reconstructed
from the publication of the CheckMate 214 study.
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Table 1
Performance of the difference and ratio of average hazard with survival weight, and Cox’s hazard ratio with sample
size 100 per arm.
Event time distribution pattern: No difference
DAH-SW RAH-SW Cox’s HR
Censoring True Bias CP AL True Bias CP AL True Bias CP AL
None 0.000 0.000 0.950 0.070 1.000 0.018 0.948 0.720 1.000 0.018 0.952 0.727
Light 0.000 -0.000 0.947 0.075 1.000 0.016 0.946 0.774 1.000 0.015 0.950 0.779
Heavy 0.000 -0.000 0.949 0.086 1.000 0.025 0.949 0.911 1.000 0.024 0.953 0.880
Event time distribution pattern: PH difference
DAH-SW RAH-SW Cox’s HR
Censoring True Bias CP AL True Bias CP AL True Bias CP AL
None -0.020 -0.000 0.950 0.065 0.800 0.013 0.949 0.597 0.800 0.014 0.951 0.603
Light -0.020 -0.000 0.950 0.070 0.800 0.014 0.949 0.645 0.800 0.015 0.952 0.649
Heavy -0.020 -0.000 0.944 0.081 0.800 0.019 0.946 0.760 0.800 0.018 0.952 0.733
Event time distribution pattern: Early difference
DAH-SW RAH-SW Cox’s HR
Censoring True Bias CP AL True Bias CP AL True Bias CP AL
None -0.010 -0.000 0.952 0.063 0.903 0.014 0.949 0.616 0.901 0.017 0.951 0.655
Light -0.010 -0.000 0.950 0.068 0.903 0.014 0.949 0.669 0.901 -0.018 0.947 0.683
Heavy -0.010 -0.000 0.944 0.080 0.903 0.020 0.946 0.800 0.901 -0.080 0.920 0.728
Event time distribution pattern: Delayed difference
DAH-SW RAH-SW Cox’s HR
Censoring True Bias CP AL True Bias CP AL True Bias CP AL
None -0.025 -0.000 0.950 0.065 0.754 0.013 0.948 0.589 0.759 0.013 0.950 0.583
Light -0.025 -0.000 0.949 0.070 0.754 0.014 0.947 0.633 0.759 0.030 0.947 0.638
Heavy -0.025 -0.000 0.943 0.080 0.754 0.020 0.943 0.739 0.759 0.064 0.944 0.741
Event time distribution pattern: 1A, no difference; 1B, PH difference; 1C, early difference; 1D, delayed difference
(see Figure 1). Censoring time distribution pattern: 2-I, no censoring; 2-II, light censoring; 2-III, heavy censoring
(see Figure 2).
Abbreviations: DAH-SW, difference in average hazard with the survival weight; RAH-SW, ratio of average hazard
with the survival weight; HR, hazard ratio; PH, proportional hazards; Censoring, censoring time distribution
pattern; True, the true value; Bias, the empirical bias (estimate minus true value); CP, the empirical coverage
probability of the 0.95 confidence interval; AL, the average length of the 0.95 confidence interval.
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Table 2
Performance of the difference and ratio of average hazard with survival weight, and Cox’s hazard ratio with sample
size 300 per arm.
Event time distribution pattern: No difference
DAH-SW RAH-SW Cox’s HR
Censoring True Bias CP AL True Bias CP AL True Bias CP AL
None 0.000 0.000 0.950 0.040 1.000 0.006 0.949 0.407 1.000 0.006 0.950 0.408
Light 0.000 -0.000 0.950 0.043 1.000 0.003 0.950 0.436 1.000 0.003 0.951 0.436
Heavy 0.000 -0.000 0.947 0.050 1.000 0.007 0.948 0.510 1.000 0.007 0.952 0.488
Event time distribution pattern: PH difference
DAH-SW RAH-SW Cox’s HR
Censoring True Bias CP AL True Bias CP AL True Bias CP AL
None -0.020 -0.000 0.950 0.037 0.800 0.005 0.950 0.338 0.800 0.005 0.952 0.339
Light -0.020 -0.000 0.952 0.040 0.800 0.004 0.952 0.364 0.800 0.005 0.954 0.363
Heavy -0.020 -0.000 0.950 0.047 0.800 0.006 0.952 0.426 0.800 0.006 0.951 0.406
Event time distribution pattern: Early difference
DAH-SW RAH-SW Cox’s HR
Censoring True Bias CP AL True Bias CP AL True Bias CP AL
None -0.010 0.000 0.950 0.037 0.903 0.005 0.949 0.349 0.901 0.006 0.949 0.368
Light -0.010 -0.000 0.951 0.040 0.903 0.005 0.952 0.379 0.901 -0.029 0.934 0.383
Heavy -0.010 -0.000 0.949 0.047 0.903 0.006 0.950 0.450 0.901 -0.091 0.854 0.404
Event time distribution pattern: Delayed difference
DAH-SW RAH-SW Cox’s HR
Censoring True Bias CP AL True Bias CP AL True Bias CP AL
None -0.025 0.000 0.952 0.038 0.754 0.005 0.950 0.332 0.759 0.005 0.949 0.328
Light -0.025 -0.000 0.949 0.040 0.754 0.004 0.950 0.356 0.759 0.020 0.946 0.356
Heavy -0.025 -0.000 0.948 0.047 0.754 0.006 0.946 0.412 0.759 0.051 0.927 0.411
Event time distribution pattern: 1A, no difference; 1B, PH difference; 1C, early difference; 1D, delayed difference
(see Figure 1). Censoring time distribution pattern: 2-I, no censoring; 2-II, light censoring; 2-III, heavy censoring
(see Figure 2).
Abbreviations: DAH-SW, difference in average hazard with the survival weight; RAH-SW, ratio of average hazard
with the survival weight; HR, hazard ratio; PH, proportional hazards; Censoring, censoring time distribution
pattern; True, the true value; Bias, the empirical bias (estimate minus true value); CP, the empirical coverage
probability of the 0.95 confidence interval; AL, the average length of the 0.95 confidence interval.
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Table 3
Size and power of tests based on difference in average hazard, ratio of average hazard, Cox’s hazard ratio, ratio of
τ -year event rate, and ratio of restricted mean survival time for sample size of 100 per arm.
Size of tests
Event time distribution pattern: No difference
Test
Censoring DAH-SW RAH-SW Cox’s HR Ratio (τ -year) Ratio (RMST)
None 0.050 0.052 0.048 0.050 0.051
Light 0.053 0.054 0.050 0.055 0.056
Heavy 0.051 0.051 0.047 0.059 0.056
Power of tests
Event time distribution pattern: PH difference
Test
Censoring DAH-SW RAH-SW Cox’s HR Ratio (τ -year) Ratio (RMST)
None 0.226 0.228 0.221 0.216 0.201
Light 0.206 0.208 0.205 0.190 0.193
Heavy 0.167 0.169 0.166 0.155 0.179
Event time distribution pattern: Early difference
Test
Censoring DAH-SW RAH-SW Cox’s HR Ratio (τ -year) Ratio (RMST)
None 0.086 0.093 0.086 0.050 0.291
Light 0.081 0.087 0.112 0.048 0.278
Heavy 0.079 0.081 0.167 0.064 0.252
Event time distribution pattern: Delayed difference
Test
Censoring DAH-SW RAH-SW Cox’s HR Ratio (τ -year) Ratio (RMST)
None 0.315 0.313 0.305 0.396 0.171
Light 0.281 0.279 0.242 0.341 0.163
Heavy 0.229 0.229 0.156 0.255 0.153
Event time distribution pattern: 1A, no difference; 1B, PH difference; 1C,
early difference; 1D, delayed difference (see Figure 1). Censoring time
distribution pattern: 2-I, no censoring; 2-II, light censoring; 2-III, heavy
censoring (see Figure 2).
Abbreviations: DAH-SW, difference in average hazard with the survival
weight; RAH-SW, ratio of average hazard with the survival weight; HR,
hazard ratio; Ratio (τ -year), ratio of τ -year event rate; Ratio (RMST),
ratio of restricted mean survival time; PH, proportional hazards; Censoring,
censoring time distribution patterns.
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Table 4
Size and power of tests based on difference in average hazard, ratio of average hazard, Cox’s hazard ratio, ratio of
τ -year event rate, and ratio of restricted mean survival time for sample size of 300 per arm.
Size of tests
Event time distribution pattern: No difference
Test
Censoring DAH-SW RAH-SW Cox’s HR Ratio (τ -year) Ratio (RMST)
None 0.050 0.051 0.050 0.050 0.049
Light 0.050 0.050 0.049 0.050 0.052
Heavy 0.053 0.052 0.048 0.055 0.051
Power of tests
Event time distribution pattern: PH difference
Test
Censoring DAH-SW RAH-SW Cox’s HR Ratio (τ -year) Ratio (RMST)
None 0.553 0.555 0.551 0.537 0.486
Light 0.503 0.505 0.502 0.460 0.460
Heavy 0.391 0.394 0.417 0.324 0.414
Event time distribution pattern: Early difference
Test
Censoring DAH-SW RAH-SW Cox’s HR Ratio (τ -year) Ratio (RMST)
None 0.175 0.182 0.172 0.050 0.676
Light 0.157 0.163 0.248 0.049 0.647
Heavy 0.123 0.128 0.402 0.057 0.582
Event time distribution pattern: Delayed difference
Test
Censoring DAH-SW RAH-SW Cox’s HR Ratio (τ -year) Ratio (RMST)
None 0.717 0.715 0.710 0.831 0.399
Light 0.674 0.672 0.596 0.760 0.372
Heavy 0.549 0.549 0.400 0.595 0.341
Event time distribution pattern: 1A, no difference; 1B, PH difference; 1C,
early difference; 1D, delayed difference (see Figure 1). Censoring time
distribution pattern: 2-I, no censoring; 2-II, light censoring; 2-III, heavy
censoring (see Figure 2).
Abbreviations: DAH-SW, difference in average hazard with the survival
weight; RAH-SW, ratio of average hazard with the survival weight; HR,
hazard ratio; Ratio (τ -year), ratio of τ -year event rate; Ratio (RMST),
ratio of restricted mean survival time; PH, proportional hazards; Censoring,
censoring time distribution patterns.
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Table 5
Estimated τ -year event rates, restricted mean survival times, and average hazards with survival weight for treatment
group (nivolumab plus ipilimumab) and control group (sunitinib) with the data reconstructed from the publication of
the CheckMate 214 study.
Treatment (0.95CI) Control (0.95CI) Difference∗ (0.95CI; p-value) Ratio∗∗ (0.95CI; p-value)
τ -year event rate [%] 60.0 (54.6 to 65.3) 71.5 (66.4 to 76.9) -11.5 (-19.3 to -3.8; 0.004) 0.8 (0.7 to 0.9; 0.003)
RMST [month] 12.2 (11.4 to 13.0) 11.0 (10.2 to 11.8) 1.2 (0.0 to 2.4; 0.043) 1.1 (1.0 to 1.2; 0.041)
AH-SW 0.049 (0.042 to 0.057) 0.066 (0.057 to 0.076) -0.017 (-0.029 to -0.005; 0.006) 0.747 (0.608 to 0.917; 0.005)
Abbreviations: RMST, restricted mean survival time; AH-SW, average hazard with survival weight; 0.95CI, 0.95 confidence
interval. We set τ to be 21 months for estimating the τ -year event rate, RMST, and AH-SW.
* Difference: Treatment − Control. A value below 0 is in favor of treatment group for τ -year event rate and AH-SW, and that
above 0 is in favor of treatment group for RMST.
** Ratio: Treatment/Control. A value below 1 is in favor of treatment group for τ -year event rate and AH-SW, and that above
1 is in favor of treatment group for RMST.
